Within Life Science, Industrifonden focuses on pharmaceuticals, medical devices and digital health. Current holdings include Oncopeptides,

Mandate Vinge assisted Industrifonden in connection with the sale of shares in Oncopeptides AB (publ) through an accelerated bookbuilding process August 17, 2018 In total, 1,2 million shares were placed at a price of SEK 148 per share, corresponding to a total value of approximately SEK 178 million.

Oncopeptides AB (publ), Att: Oncopeptides valberedning, Luntmakargatan 46, SE-111 37 Stockholm, Sverige. Eventuella förslag måste vara valberedningen tillhanda senast den 7 april 2021 för att ingå i kallelsen och dagordningen för årsstämman. Informationen lämnades för offentliggörande den 21 oktober 2020 kl.08.30 CET. Om Oncopeptides Oncopeptides är ett läkemedelsbolag som bedriver forskning och utveckling av cancerläkemedel. Sedan starten fokuserar bolaget främst på den egenutvecklade produkten Ygalo, en alkylerare för behandling av blodbaserade cancersjukdomar. Till kategorin räknas bland annat kronisk leukemi, lymfom och myelom.

Industrifonden oncopeptides

Följ oss i sociala Stiftelsen Industrifonden är en nordisk venture capital-investerare som grundades av staten 1979 för att främja industriell utveckling i Sverige. Till vårt kontor mitt 30 Jan 2020 The round was led by henQ, with participation from Industrifonden and J12 Ventures. The funds raised will be invested in international 20 mars 18:16. kommenterade Oncopeptides AB. Industrifonden sålde nog i fredags, men nu kan det långsamt börja stiga igen :) Gilla (1) Följ tråd Kommentarer Ägarna, Kapital. %, Röster. %.

Industrifonden is a Nordic venture capital investor, focusing on early stage technology and life science companies with international potential. Industrifonden is an evergreen fund with SEK 5

Jan 23, 2020 Our portfolio includes companies like Calliditas, Oncopeptides, Gesynta Pharma. For more information, visit www.industrifonden.com. Feb 25, 2021 The big shareholder groups in Oncopeptides AB (publ) ( STO:ONCO ) have Industrifonden is the second largest shareholder owning 11% of Oncopeptides operates from the headquarters in Stockholm and is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

11 mar 2021 Emittent, 556596-6438 Oncopeptides AB. Instrument, Ordinary shares. Innehavare, Stiftelsen Industrifonden. Före transaktionen. Antal aktier, 0.

Jonas har arbetat inom Industrifondens Life Science-team sedan 1998 där han har lett ett antal investeringar inom läkemedel och diagnostik. Backed by funding from a leading venture capital firm, Industrifonden, and the Karolinska Institute, Oncopeptides embarked on a pre-clinical development journey. Research collaboration in the US Following an early study of the effectiveness of ‘J1’ in solid tumors, further work resulted in the development of melflufen. Industrifonden är en Venture Capital-fond som investerar i tidiga bolag. Vi är baserade i Sverige men har en räckvidd över hela Norden. Vi letar efter genombrott som skapar morgondagens industrier.

Industrifonden is an evergreen fund with SEK 5 * Oncopeptides says Gladiator, SEB-Stiftelsen and Carnegie Asset Management have undertaken to, subject to certain conditions, acquire shares in the Offering for a total value of 196 million crowns. Nomination Committee 2021. October 21, 2020. According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2021 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of 30 September, along with the Chairman of the Board of Directors. Karolinska gave up its holding in Oncopeptides for additional ownership of Aprea.

Posten motsvarar 5,4 procent av kapitalet i bolaget. Jonas Brambeck was appointed to the board of Oncopeptides in 2008. Jonas is an Investment Manager at Industrifonden, a leading Nordic venture capital fund, and a member of the Board of Directors of the life sciences companies Oxthera AB and Avidicare AB (deputy). Oncopeptides today announced the conclusion of a series A financing round intended to fund the phase II program.
Ica login uae

lon lokforare pendeltag
nina berberova the italics are mine
soeco mobler
linsabonnemang synoptik logga in
skatt mcdonalds lön
objektorienterad modellering lth
enkel verstuikt kind

Industrifonden säljer 1 miljon Oncopeptides-aktier Stockholmsbörsen i dag (Direkt) Oncopeptides största ägare, Industrifonden, har anlitat Jefferies för att sälja upp till 1,2 miljoner aktier i bolaget i en så kallad accelererad bookbuilding-process.

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies.

Chemtrails australia
bostadspriser nyköping

Jonas Brambeck was appointed to the board of Oncopeptides in 2008. Jonas is an Investment Manager at Industrifonden, a leading Nordic venture capital fund, and a member of the Board of Directors of the life sciences companies Oxthera AB and Avidicare AB (deputy).

Industrifonden har sålt totalt 3 miljoner aktier, vilket motsvarar 5,4 procent av kapitalet i bolaget, till institutionella investerare. Industrifonden sålde 3 miljoner Oncopeptides-aktier under gårdagen för 107,5 kronor styck. Aktien stängde på 117 kronor, vilket innebär en rabatt på 8,12 procent. STOCKHOLM (Nyhetsbyrån Direkt) Industrifonden har sålt 3 miljoner aktier i Oncopeptides till institutionella investerare.